Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4813-4821

  Howe, Anita Y M ^a   Bloom, Johnathan ^a   Baldick, Carl J ^a,c   Benetatos, Christopher A ^b   Cheng, Huiming ^a   Christensen, Joel S ^b   Chunduru, Srinivas K ^b   Coburn, Glen A ^b   Feld, Boris ^a   Gopalsamy, Ariamala ^a   Gorczyca, William P ^b,d   Herrmann, Steve ^a   Johann, Stephen ^a   Jiang, Xiaoqun ^a   Kimberland, Michelle L ^b   Krisnamurthy, Girija ^a   Olson, Matthew ^a   Orlowski, Mark ^a   Swanberg, Steve ^a   Thompson, Ian ^a   Thorn, Megan ^a   Vecchio, Alfred Del ^b,e   Young, Dorothy C ^b   Van Zeijl, Marja ^a   Ellingboe, John W ^a   Upeslacis, Janis ^a   Collett, Marc ^b   Mansour, Tarek S ^a   O'Connell, John F ^a   more..

^a WYETH RESEARCH   (United States)

^b ViroPharma Incorporated   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(5 CYANO 8 METHYL 1 PROPYL 1,3,4,9, TETRAHYDROPYANO[3,4 B]INDOL 1 YL)ACETIC ACID; DNA DIRECTED DNA POLYMERASE GAMMA; PEGINTERFERON; PEGINTERFERON ALPHA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; GENOTYPE; HAMSTER; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MITOCHONDRION; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REPLICON; STEADY STATE; VIRUS GENOME; VIRUS INFECTION; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESCHERICHIA COLI; HEPACIVIRUS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INDOLES; INTERFERON-ALPHA; PYRANS; REPLICON; RNA REPLICASE; SPECTROMETRY, FLUORESCENCE; SUBSTRATE SPECIFICITY; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 9644290930     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4813-4821.2004     Document Type: Article

References (47)

1. Baginski, S. G., D. C. Pevear, M. Seipel, S. C. Sun, C. A. Benetatos, S. K. Chunduru, C. M. Rice, and M. S. Collett. 2000. Mechanism of action of a pestivirus antiviral compound. Proc. Natl. Acad. Sci. USA 97:7981-7986.
2. Billich, A. 2001. Entecavir (Bristol-Myers Squibb). Curr. Opin. Investig. Drugs 2:617-621.
3. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
4. Buti, M., and R. Esteban. 2003. Adefovir dipivoxil. Drugs Today 39:127-135.
5. Campbell, J. L. 1986. Eukaryotic DNA replication. Annu. Rev. Biochem. 55:733-771.
6. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. C. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
7. Chan, L., T. J. Reddy, M. Proulx, S. K. Das, O. Pereira, M. Courchesne, C. Roy, C. Yannopoulos, C. Poisson, N. Nguyen-Ba, L. Halab, R. Bethell, M.-Q. Zhang, M. David, L. L'Heureux, J. Bedard, M. Kamel, and O. Nicolas. 2003. Discovery of a novel class of HCV NS5B RNA dependent RNA polymerase inhibitors: SAR studies and activity in replicon cells. Antivir. Res. 57:A76.
8. Dhanak, D., K. J. Duffy, V. K. Johnston, J. Lin-Goerke, M. Darcy, A. N. Shaw, B. Gu, C. Silverman, A. T. Gates, M. R. Nonnemacher, D. L. Earnshaw, D. J. Casper, A. Kaura, A. Baker, C. Greenwood, L. L. Gutshall, D. Maley, A. DelVecchio, R. Macarron, G. A. Hofmann, Z. Alnoah, H. Y. Cheng, G. Chan, S. Khandekar, R. M. Keenan, and R. T. Sarisky. 2002. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277:38322-38327.
9. Ferrari, E., J. Wright-Minogue, J. W. S. Fang, B. M. Baroudy, J. Y. N. Lau, and Z. Hong. 1999. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 73:1649-1654.
10. Jamieson, E. R., M. P. Jacobson, C. M. Barnes, C. S. Chow, and S. J. Lippard. 1999. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B. J. Biol. Chem. 274:12346-12354.
11. Johnson, L. M., M. Snyder, L. M. Chang, R. W. Davis, and J. L. Campbell. 1985. Isolation of the gene encoding yeast DNA polymerase I. Cell 43:369-377.
12. Jones, T. R., V. P. Muzithras, and Y. Gluzman. 1991. Replacement mutagenesis of the human cytomegalovirus genome: US10 and US11 gene products are nonessential. J. Virol. 65:5860-5872.
13. Khakoo, S., P. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G. M. Dusheiko, 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 46:563-570.
14. Kim, J. L., K. A. Morgenstern, J. P. Griffith, M. D. Dwyer, J. A. Thomson, M. A. Murcko, C. Lin, and P. R. Caron, 1998. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6:89-100.
15. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
16. Lehman, I. R., and L. S. Kaguni. 1989. DNA polymerase alpha. J. Biol. Chem. 264:4265-4268.
17. Liang, T. J., B. Rehermann, L. B. Seeff, and J. H. Hoofnagle. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296-305.
18. Lohmann, V., J. O. Koch, and R. Bartenschlager. 1996. Processing pathways of the hepatitis C virus proteins. J. Hepatol. 24:11-19.
19. Lohmann, V., F. Korner, U. Herian, and R. Bartenschlager. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428.
20. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
21. Lohmann, V., A. Roos, F. Korner, J. O. Koch, and R. Bartenschlager. 1998. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 249:108-118.
22. Maldonado, E., R. Drapkin, and D. Reinberg. 1996. Purification of human RNA polymerase II and general transcription factors. Methods Enzymol. 274:72-100.
23. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
24. Mercer, D. F., D. E. Schiller, J. F. Elliott, D. N. Douglas, C. Hao, A. Rinfret, W. R. Addison, K. P. Fischer, T. A. Churchill, J. R. Lakey, D. L. Tyrrell, and N. M. Kneteman. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:927-933.
25. Miller, M. D., N. A. Margot, P. D. Lamy, M. D. Fuller, K. E. Anton, A. S. Mulato, and J. M. Cherrington. 2001. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J. Acquir. Immune Defic. Syndr. 27:450-458.
26. Mizokami, M., and K. Ohba. 1993. Molecular classification of hepatitis C virus. Gastroenterol. Jpn. 28:42-44.
27. Oh, J. M., J. Kyun, and S. W. Cho. 2002. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis. Pharmacotherapy 22:1226-1234.
28. Pietschmann, T., V. Lohmann, G. Rutter, K. Kurpanek, and R. Bartenschlager. 2001. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:1252-1264.
29. Prichard, M. N., L. E. Prichard, and C. Shipman. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
30. Prichard, M. N., and C. Shipman. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir. Res. 1:9-20.
31. Prichard, M. N., and C. Shipman, 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
32. Reichard, O., G. Norkrans, A. Fryden, J. H. Braconier, A. Sonnerborg, O. Weiland, and the Swedish Study Group. 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87.
33. Russo, M. W., and M. W. Fried. 2003. Side effects of therapy for chronic hepatitis C. Gastroenterology 124:1711-1719.
34. Simmonds, P. 1996. Virology of hepatitis C virus. Clin. Ther. 18:9-36.
35. Spruance, S. L., S. K. Tyring, B. DeGregorio, C. Miller, K. Beutner, and the Valaciclovir HSV Study Group. 1996. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. 156:1729-1735.
36. Squires, K., A. L. Pozniak, G. Pierone, Jr., C. R. Steinhart, D. Berger, N. C. Bellos, S. L. Becker, M. Wulfsohn, M. D. Miller, J. J. Toole, D. F. Coakley, A. Cheng, and T. Study. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann. Intern. Med. 139:313-320.
37. Stuyver, L. J., T. Whitaker, T. R. McBrayer, B. I. Hernandez-Santiago, S. Lostia, P. M. Tharnish, M. Ramesh, C. K. Chu, R. Jordan, J. Shi, S. Rachakonda, K. A. Watanabe, M. J. Otto, and R. F. Schinazi. 2003. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 47:244-254.
38. Summa, V., A. Petrocchi, P. Pace, V. G. Matassa, R. De Francesco, S. Altamura, L. Tomei, U. Koch, and P. Neuner. 2004. Discovery of α,γ-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem. 47:14-17.
39. Takamizawa, A., C. Mori, I. Fuke, S. Manabe, S. Murakami, J. Fujita, E. Onishi, T. Andoh, I. Yoshida, and H. Okayama. 1991. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65:1105-1113.
40. Tomei, L., R. L. Vitale, I. Incitti, S. Serafini, S. Altamura, A. Vitelli, and R. De Francesco. 2000. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J. Gen. Virol. 81:759-767.
41. Wald, A., J. Zeh, G. Barnum, L. G. Davis, and L. Corey. 1996. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 124:8-15.
42. Walker, C. M. 1997. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin. Immunopathol. 19:85-98.
43. Wang, M. T., K. K. S. Ng, M. M. Cherney, L. Chan, C. G. Yannopoulos, J. Bedard, N. Morin, N. Nguyen-Ba, M. H. Alaoui-Ismaili, R. C. Bethell, and M. N. G. James. 2003. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278:9489-9495.
44. Wang, T. S., W. C. Copeland, L. Rogge, and Q. Dong. 1995. Purification of mammalian DNA polymerases: DNA polymerase alpha. Methods Enzymol. 262:77-84.
45. World Health Organization. 1998. WHO concerns on hepatitis C. Lancet 351:1415.
46. Yogev, R., S. Lee, A. Wiznia, S. Nachman, K. Stanley, S. Pelton, L. Mofenson, S. Fiscus, E. Jimenez, M. H. Rathore, M. E. Smith, L. Y. Song, K. McIntosh, and the Pediatrics AIDS Clinical Trials Group 388 Study Team. 2002. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 21:119-125.
47. Zeuzem, S., S. V. Feinman, J. Rasenack, E. J. Heathcote, M. Y. Lai, E. Gane, J. O'Grady, J. Reichen, M. Diago, A Lin, J. Hoffman, and M. J. Brunda. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:1666-1672.